Shares of Masimo Co. (NASDAQ:MASI) have been assigned a consensus recommendation of “Hold” from the seven research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $106.25.
A number of research analysts have recently commented on MASI shares. Zacks Investment Research raised shares of Masimo from a “hold” rating to a “buy” rating and set a $98.00 price objective for the company in a research report on Thursday, November 2nd. BidaskClub downgraded shares of Masimo from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $108.00 price objective on shares of Masimo in a research report on Friday, November 3rd.
In related news, EVP Yongsam Lee sold 18,198 shares of Masimo stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $88.85, for a total transaction of $1,616,892.30. Following the completion of the sale, the executive vice president now owns 70,800 shares of the company’s stock, valued at approximately $6,290,580. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Sanford Fitch sold 2,000 shares of Masimo stock in a transaction dated Thursday, January 25th. The stock was sold at an average price of $90.00, for a total transaction of $180,000.00. Following the sale, the director now directly owns 70,249 shares of the company’s stock, valued at approximately $6,322,410. The disclosure for this sale can be found here. Insiders have sold a total of 48,098 shares of company stock valued at $4,315,261 in the last ninety days. 16.60% of the stock is currently owned by insiders.
Hedge funds have recently made changes to their positions in the stock. State Street Corp boosted its holdings in shares of Masimo by 10.4% during the 2nd quarter. State Street Corp now owns 1,547,728 shares of the medical equipment provider’s stock worth $141,121,000 after buying an additional 146,212 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Masimo by 6.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,074,648 shares of the medical equipment provider’s stock worth $93,021,000 after buying an additional 64,882 shares during the period. Eagle Asset Management Inc. boosted its holdings in shares of Masimo by 6.1% during the 3rd quarter. Eagle Asset Management Inc. now owns 32,772 shares of the medical equipment provider’s stock worth $2,847,000 after buying an additional 1,870 shares during the period. Public Employees Retirement System of Ohio boosted its holdings in shares of Masimo by 143.1% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 37,045 shares of the medical equipment provider’s stock worth $3,207,000 after buying an additional 21,807 shares during the period. Finally, Nine Chapters Capital Management LLC acquired a new stake in Masimo in the 3rd quarter worth about $545,000. 82.30% of the stock is owned by institutional investors and hedge funds.
Masimo (NASDAQ:MASI) opened at $86.68 on Friday. Masimo has a 12-month low of $79.81 and a 12-month high of $104.71. The company has a market cap of $4,480.00, a PE ratio of 13.74, a PEG ratio of 3.23 and a beta of 0.85.
TRADEMARK VIOLATION WARNING: “Masimo Co. (MASI) Receives Consensus Rating of “Hold” from Brokerages” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://ledgergazette.com/2018/02/17/masimo-co-masi-receives-consensus-rating-of-hold-from-brokerages.html.
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.